Summit Therapeutics (SMMT) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to 0.73.
- Summit Therapeutics' Equity Ratio fell 1564.92% to 0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73, marking a year-over-year decrease of 1564.92%. This contributed to the annual value of 0.89 for FY2024, which is 13314.75% up from last year.
- Latest data reveals that Summit Therapeutics reported Equity Ratio of 0.73 as of Q3 2025, which was down 1564.92% from 0.8 recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Equity Ratio ranged from a high of 0.9 in Q1 2025 and a low of 0.19 during Q4 2022
- Moreover, its 5-year median value for Equity Ratio was 0.57 (2024), whereas its average is 0.62.
- In the last 5 years, Summit Therapeutics' Equity Ratio tumbled by 7404.07% in 2022 and then surged by 25872.37% in 2025.
- Over the past 5 years, Summit Therapeutics' Equity Ratio (Quarter) stood at 0.73 in 2021, then plummeted by 74.04% to 0.19 in 2022, then surged by 100.75% to 0.38 in 2023, then skyrocketed by 133.15% to 0.89 in 2024, then fell by 17.7% to 0.73 in 2025.
- Its Equity Ratio stands at 0.73 for Q3 2025, versus 0.8 for Q2 2025 and 0.9 for Q1 2025.